Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 2, 2021

Nanomix resubmits EUA application to FDA for Covid-19 rapid antigen test

The eLab Covid-19 rapid antigen test delivers results within 15 minutes.

Nanomix has resubmitted an application to the US Food and Drug Administration (FDA) seeking emergency use authorization (EUA) for its eLab COVID-19 rapid antigen test.

The latest move follows the submission of an application for EUA to the FDA for the same product in February.

The new application from Nanomix includes clinical development documentation as well as additional analytical data in response to review comments from the FDA.

The portable, handheld eLab COVID-19 rapid antigen test, which runs on the portable Nanomix eLab analyser, delivers results within 15 minutes.

It delivers laboratory-quality results in any setting to help expand the access and availability of testing for Covid-19.

The assay uses nasal swab samples and detects nucleocapsid antigens from SARS-CoV-2.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

A swab and nasal sample collection tube are used to collect samples from the user and transferred to the single-use, microfluidic cartridge.

The cartridge can print or deliver results electronically through Bluetooth.

The point-of-care antigen system can also publish the test results as a QR code for privacy.

Nanomix president and CEO David Ludvigson said: “We look forward to the FDA’s review of our application and are proud of the work our team has done to develop a rapid, portable Covid-19 antigen test during this critical time.

“If authorised by the FDA, we believe our mobile point-of-care system will greatly increase accessibility to Covid-19 testing.”

The company stated that the development project secured federal funds, either in whole or in part, from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, and Biomedical Advanced Research and Development Authority (BARDA) Division of Research Innovation and Ventures.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy